“CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that it has raised $10 million in a Series A round from Qiming Venture Partners and TF Capital, a venture fund initiated by the leading Chinese CRO, Tigermed. Foun
“CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that it has raised $10 million in a Series A round from Qiming Venture Partners and TF Capital, a venture fund initiated by the leading Chinese CRO, Tigermed. Foun
このブックマークにはスターがありません。
最初のスターをつけてみよう！
PharmaAsia.com
1 人がブックマーク・1 件のコメント
＼ コメントが サクサク読める アプリです ／